14:46 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

MaaT completes enrollment in Phase Ib of MaaT001 for dysbiosis

MaaT Pharma S.A. (Lyon, France) completed enrollment of 25 acute myelogenous leukemia (AML) patients with iatrogenic dysbiosis induced by chemotherapy or antibiotics in the Phase Ib Odyssée trial evaluating MaaT001. Patients will receive MaaT001 delivered...
03:08 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Autologous fecal microbiota transplantation: Ph Ib ongoing

An independent DSMB recommended continuation of the open-label, French Phase Ib ODYSSEE trial evaluating autologous fecal microbiota transplantation in about 35 patients with acute myelogenous leukemia (AML) undergoing intensive induction chemotherapy. MaaT Pharma S.A. ,...
07:00 , May 9, 2016 |  BioCentury  |  Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...